Project Grant R01HL183174
- Federal Project Grant Summary The University of Pittsburgh received a $1,420,780 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with completion targeted for May 31, 2029. The grant funds basic and translational research to elucidate the mechanistic requirements of ALK1 (Activin Receptor-Like Kinase 1) ligands—specifically bone morphogenetic proteins 9 and 10 (BMP9 and...
- Federal Grant Award Summary The University of Pittsburgh received a $109,076 Project Grant award from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 10, 2025, with completion targeted for September 9, 2029. Based on the award documentation and program parameters, this funding supports hypothesis-driven research in cardiovascular science, consistent with NHLBI's mission to advance prevention and...
- Federal Grant Award Summary The University of Pittsburgh received a $410,139 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 10, 2025, with completion targeted for May 31, 2027. The project, "Advancing Aortic Aneurysm Strength Predictions: A Novel Density-Driven Strength Assessment Tool," develops innovative methods to predict thoracic aortic aneurysm (TAA) failure risk by...
- Federal Project Grant Award Summary The University of Pittsburgh received a $593,985 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2029. The project develops artificial intelligence (AI) techniques and systems that convert photoplethysmography (PPG) measurements from off-the-shelf wearable devices into multi-lead electrocardiogram (ECG)...
- Federal Grant Award Summary The University of Pittsburgh received $782,341 in funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant awarded July 15, 2026, with completion targeted for May 31, 2031. The project will develop and validate an adaptive, artificial intelligence-guided, closed-loop neuromodulation system designed to predict and prevent ventricular arrhythmias (VAs)—including ventricular...
- Federal Project Grant Award Summary The University of Pittsburgh received a $1,559,091 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 10, 2026, with completion targeted for April 30, 2028. This award supports the development and validation of a novel positron emission tomography (PET) imaging approach targeting chemokine-like receptor 1 (CMKLR1) to noninvasively monitor macrophage-driven...
- Federal Project Grant Award Summary The University of Pittsburgh received a $756,607 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, with completion targeted for April 30, 2033. This award funds basic and translational research investigating the therapeutic potential of enhancing macrophage lysosomal degradative capacity as a novel intervention strategy for atherosclerosis and...
- Federal Project Grant Award Summary The University of Pittsburgh received a $100,228 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2026, with completion targeted for April 30, 2028. This award funds mechanistic research investigating how regulatory T cells (Tregs) respond to interleukin-33 (IL-33) signaling in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)...
- Federal Project Grant Award Summary The University of Pittsburgh received a $1,019,556 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 13, 2026, for development and implementation of "The Hypertension Toolkit: An Adaptive Mobile Health Blood Pressure Intervention." The primary deliverable is a theory-informed chronic disease self-management intervention targeting blood pressure...
- Federal Grant Award Summary The University of Pittsburgh received a $2,366,589 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2026, with completion targeted for February 29, 2028. The grant funds research into the manipulation of leucine uptake, sensing, and metabolism in macrophages as both a diagnostic and therapeutic strategy for atherosclerosis. The research builds on a decade...
The University of Pittsburgh received $767,953 in funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for a project titled "Structural Biomimicry to Improve Engineered Heart Valve Leaflet Function and Remodeling." The award was obligated on July 1, 2026, with an ultimate completion date of March 31, 2030. This project addresses critical gaps in tissue-engineered heart valve (TEHV) development, specifically focusing on pulmonary insufficiency issues observed in clinical trials caused by premature polymer degradation and inadequate leaflet thickness distribution. The primary deliverables under this grant include the fabrication and validation of bio-inspired engineered pulmonary valve (bi-PV) prototypes that replicate native leaflet structure and function. Through this research initiative, the University of Pittsburgh will develop an advanced biomaterial platform and processing methodology designed to enhance functional performance and tissue remodeling characteristics of engineered heart valves. The project aims to establish mechanistic understanding of in-situ remodeling processes and demonstrate that recapitulating native leaflet biomimicry will yield superior outcomes for treating valve stenosis, regurgitation, and congenital valve diseases in pediatric and adult patient populations.Federal Project Grant Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $768.0k | 7/8/26 |